David Joseph Gaffin, the EVP of $ALKS, sold 2,034 shares of the company on 04-06-2026 for an estimated $70,315. We received data on the trade from a recent SEC filing. This was a sale of approximately 0.9% of their shares of this class of stock. Following this trade, they now own 233,592 shares of this class of $ALKS stock.
$ALKS Insider Trading Activity
$ALKS insiders have traded $ALKS stock on the open market 17 times in the past 6 months. Of those trades, 0 have been purchases and 17 have been sales.
Here’s a breakdown of recent trading of $ALKS stock by insiders over the last 6 months:
- SHANE COOKE has made 0 purchases and 2 sales selling 61,200 shares for an estimated $2,115,672.
- CRAIG C. HOPKINSON (EVP R&D, Chief Medical Officer) has made 0 purchases and 10 sales selling 61,748 shares for an estimated $1,941,344.
- SAMUEL JOSEPH PARISI (VP, Finance (Interim PAO)) sold 6,890 shares for an estimated $201,808
- DAVID JOSEPH GAFFIN (EVP, CLO, Alkermes, Inc.) has made 0 purchases and 3 sales selling 6,102 shares for an estimated $190,423.
- CHRISTIAN TODD NICHOLS (SVP, Chief Commercial Officer) sold 6,000 shares for an estimated $180,000
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$ALKS Hedge Fund Activity
We have seen 182 institutional investors add shares of $ALKS stock to their portfolio, and 171 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- RTW INVESTMENTS, LP removed 3,009,933 shares (-64.3%) from their portfolio in Q4 2025, for an estimated $84,217,925
- WELLINGTON MANAGEMENT GROUP LLP added 2,645,252 shares (+705.0%) to their portfolio in Q4 2025, for an estimated $74,014,150
- HOLOCENE ADVISORS, LP removed 2,469,030 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $69,083,459
- DEEP TRACK CAPITAL, LP added 2,000,000 shares (+inf%) to their portfolio in Q4 2025, for an estimated $55,960,000
- BAKER BROS. ADVISORS LP added 1,920,916 shares (+23.7%) to their portfolio in Q4 2025, for an estimated $53,747,229
- UBS GROUP AG added 1,790,729 shares (+237.4%) to their portfolio in Q4 2025, for an estimated $50,104,597
- PARADIGM BIOCAPITAL ADVISORS LP removed 1,719,334 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $48,106,965
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$ALKS Analyst Ratings
Wall Street analysts have issued reports on $ALKS in the last several months. We have seen 6 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Truist Securities issued a "Buy" rating on 11/17/2025
- Deutsche Bank issued a "Buy" rating on 11/13/2025
- Wells Fargo issued a "Overweight" rating on 11/13/2025
- Needham issued a "Buy" rating on 10/29/2025
- Mizuho issued a "Outperform" rating on 10/27/2025
- Piper Sandler issued a "Overweight" rating on 10/23/2025
To track analyst ratings and price targets for $ALKS, check out Quiver Quantitative's $ALKS forecast page.
$ALKS Price Targets
Multiple analysts have issued price targets for $ALKS recently. We have seen 9 analysts offer price targets for $ALKS in the last 6 months, with a median target of $45.0.
Here are some recent targets:
- David Amsellem from Piper Sandler set a target price of $43.0 on 03/24/2026
- Benjamin Burnett from Wells Fargo set a target price of $43.0 on 02/26/2026
- Leonid Timashev from RBC Capital set a target price of $45.0 on 02/26/2026
- Rudy Li from Wolfe Research set a target price of $45.0 on 02/24/2026
- Jason Gerberry from B of A Securities set a target price of $34.0 on 02/20/2026
- Joon Lee from Truist Securities set a target price of $55.0 on 11/17/2025
- David Hoang from Deutsche Bank set a target price of $45.0 on 11/13/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
